PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26467280-0	2015	Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.	Sitagliptin Phosphate	34-45	fatty acid binding protein 4	Homo sapiens	19-24	
26467280-4	2015	Treatment with sitagliptin decreased serum FABP4 concentration by 19.7% (17.8 +- 1.8 vs. 14.3 +- 1.5 ng/ml, P < 0.001) and hemoglobin A1c without significant changes in adiposity or lipid variables.	Sitagliptin Phosphate	15-26	fatty acid binding protein 4	Homo sapiens	43-48	
26467280-6	2015	However, gene expression and long-term (24 h) secretion of FABP4 were significantly reduced by sitagliptin, which was not mimicked by exendin-4.	Sitagliptin Phosphate	95-106	fatty acid binding protein 4	Homo sapiens	59-64	
26467280-9	2015	In conclusion, sitagliptin decreases serum FABP4 level, at least in part, via reduction in the expression and consecutive secretion of FABP4 in adipocytes by direct inhibition of DPP-4.	Sitagliptin Phosphate	15-26	fatty acid binding protein 4	Homo sapiens	43-48	
26467280-9	2015	In conclusion, sitagliptin decreases serum FABP4 level, at least in part, via reduction in the expression and consecutive secretion of FABP4 in adipocytes by direct inhibition of DPP-4.	Sitagliptin Phosphate	15-26	fatty acid binding protein 4	Homo sapiens	135-140	
32539832-3	2020	Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naive and sulfonylurea-treated patients with type 2 diabetes mellitus.	Sitagliptin Phosphate	0-11	fatty acid binding protein 4	Homo sapiens	62-67